OSLO, Norway, July 1, 2020 /PRNewswire/ -- Photocure
ASA (OSE:PHO), today announced the appointment of Susanne Strauss as Vice President and General
Manager of Europe, effective
1 July 2020.
"I am pleased to welcome Susanne
Strauss to the Photocure team and I am confident that
Susanne's background and experience will lend itself to the success
launch of our European-wide organization this fall. Susanne
will report directly to me in her role and will be a member of
Photocure's leadership team. In addition, as part of building the
larger European organization, we will integrate our current Nordic
operation led by Kristin Nyberg
under Susanne's leadership," says Dan Schneider, President and Chief Executive
Officer of Photocure.
Ms. Strauss brings over 20 years of international leadership
experience in medical devices, life sciences and pharma, living and
working across Europe and
Asia with occasional remits in the
U.S. Most recently Ms. Strauss held the position of General Manager
of Asia Pacific for legacy BTG at
Boston Scientific based in Hong
Kong after leading BTG's Interventional Pulmonology Business
as VP Commercial and expanding BTG's Interventional Oncology
Business into Europe. Before that
she worked in leadership positions for companies such as Convatec,
Janssen-Cilag and Baxter. She holds a PhD in Technical Chemistry
and an MBA from SDA Bocconi.
The appointment follows the agreement to regain the
Hexvix® sales, marketing and distribution rights in
Europe and other markets currently
controlled by Ipsen Pharma SAS on 1 October
2020.
"To execute on this opportunity and its global strategy,
Photocure is establishing its commercial operations in Europe, with key leads already hired both at
country level and in the global functions to support the European
organization," Schneider adds. Ms. Strauss and these key
leaders will be part of the ongoing comprehensive transition
activities in collaboration with Ipsen teams. Ms. Strauss will
establish a European Headquarters, hire the European commercial
team and oversee the integration with other functions to form a
complete European organization. She will work on the development of
new growth strategies and the execution of tactics in key markets
throughout Europe.
"The transition activities are on track and Photocure is in
the process of establishing a distribution and third-party
logistics network. We are fully confident that we will be
operationally and commercially ready for a smooth handover on
October 1. The ongoing transition
activities are being facilitated by our deep knowledge of the
disease state and our product. We intend to leverage our expertise
by applying the commercial success and strong growth in the Nordic
and the U.S. markets to the European region," Schneider
concludes.
Notes to editors
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix®/Cysview® is a drug that is
selectively taken up by tumor cells in the bladder making them glow
bright pink during Blue Light Cystoscopy (BLCTM). BLC™
with Hexvix® /Cysview® improves the detection
of tumors and leads to more complete resection, fewer residual
tumors and better management decisions. Cysview® is the
tradename in the U.S. and Canada,
Hexvix® is the tradename in all other markets.
About Bladder Cancer
Bladder cancer ranks as the sixth most common cancer worldwide with
1 650 000 prevalent cases (5-year prevalence rate),
550 000 new cases and almost 200 000 deaths annually in
2018.1Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with an average of
61% in year one and 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3 and T4, are more likely to
spread and are harder to treat.4
1 Globocan. Incidence/mortality by
population. Available at: http://globocan.iarc.fr/Pages/bar_pop_sel.aspx
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol
2009;27:295-300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
For further information, please contact:
Photocure
Dan Schneider
President and CEO
Tel: +1-609-759-6515
Email: ds@photocure.com
Erik Dahl
CFO
Tel: +47-45055000
Email: ed@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47-91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/photocure-appoints-susanne-strauss-as-vice-president-and-general-manager-of-europe,c3146614
The following files are available for download:
https://mb.cision.com/Main/17498/3146614/1273071.pdf
|
Release
|
https://news.cision.com/photocure/i/susannestrauss-photocure,c2802462
|
SusanneStrauss
Photocure
|